Sutro Biopharma, Inc. (STRO) has a negative trailing P/E of -1.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -83.20%.
Criteria proven by this page:
Overall SharesGrow Score: 42/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 3.9 | 0.00 | -0.07 | 0.11 | - |
| 2017 | -5.4 | 0.03 | -0.98 | 2.06 | - |
| 2018 | -5.8 | 0.13 | 1.57 | 5.37 | - |
| 2019 | -4.5 | -0.08 | 2.58 | 5.91 | - |
| 2020 | -22.0 | 0.37 | 2.13 | 16.55 | - |
| 2021 | -6.5 | -0.05 | 2.72 | 11.09 | - |
| 2022 | -3.4 | -1.31 | 1.89 | 6.05 | - |
| 2023 | -2.4 | 0.10 | 1.72 | 1.68 | - |
| 2024 | -0.6 | -0.01 | 3.17 | 2.28 | - |
| 2025 | -0.5 | 0.02 | -0.74 | 0.96 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $0.24 | $59.73M | $1.7M | 2.8% |
| 2017 | $-2.81 | $51.74M | $-19.69M | -38.1% |
| 2018 | $-6.13 | $38.42M | $-35.32M | -91.9% |
| 2019 | $-2.43 | $42.74M | $-55.74M | -130.4% |
| 2020 | $-1.11 | $42.72M | $-36.21M | -84.7% |
| 2021 | $-2.36 | $61.88M | $-108.68M | -175.6% |
| 2022 | $-2.35 | $67.77M | $-119.2M | -175.9% |
| 2023 | $-1.78 | $153.73M | $-106.79M | -69.5% |
| 2024 | $-2.96 | $62.04M | $-227.46M | -366.6% |
| 2025 | $-22.49 | $102.48M | $-191.09M | -186.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-9.95 | $-14.35 – $-4.94 | $35M | $11.38M – $68.29M | 5 |
| 2027 | $-8.65 | $-13.93 – $-4.56 | $21.07M | $3.93M – $38.19M | 5 |
| 2028 | $-7.93 | $-14.11 – $-1.73 | $38.24M | $10.6M – $67.18M | 6 |
| 2029 | $-7.44 | $-14.75 – $-0.45 | $55M | $15.25M – $96.62M | 4 |
| 2030 | $-6.12 | $-12.14 – $-0.37 | $70.89M | $19.65M – $124.54M | 2 |
